GTXI Share Price

Open 4.83 Change Price %
High 4.88 1 Day 0.01 0.21
Low 4.69 1 Week 0.07 1.46
Close 4.88 1 Month -1.00 -17.01
Volume 21090 1 Year 4.24 662.50
52 Week High 7.49
52 Week Low 0.50
GTXI Important Levels
Resistance 2 5.06
Resistance 1 4.98
Pivot 4.82
Support 1 4.78
Support 2 4.70
NASDAQ USA Most Active Stocks
SPWR 8.98 1.01%
TFSL 17.20 0.17%
RIGL 2.52 9.57%
ADP 102.70 -0.29%
ADP 102.70 -0.29%
ADP 102.70 -0.29%
ADP 102.70 -0.29%
FNFG 10.18 -0.20%
ASTI 0.00 0.00%
REGN 373.05 3.34%
More..
NASDAQ USA Top Gainers Stocks
TEAR 5.74 983.02%
CGEI 0.37 85.00%
LOCM 0.09 50.00%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
IMGN 3.28 21.03%
VOXX 5.05 20.24%
HAUP 0.06 20.00%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
QTWW 0.08 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
More..

GTx, Inc. (NASDAQ: GTXI)

GTXI Technical Analysis 2
As on 27th Feb 2017 GTXI Share Price closed @ 4.88 and we RECOMMEND Buy for LONG-TERM with Stoploss of 1.88 & Strong Sell for SHORT-TERM with Stoploss of 5.64 we also expect STOCK to react on Following IMPORTANT LEVELS.
GTXI Target for February
1st Target up-side 6.27
2nd Target up-side 6.73
3rd Target up-side 7.19
1st Target down-side 4.97
2nd Target down-side 4.51
3rd Target down-side 4.05
GTXI Other Details
Segment EQ
Market Capital 258176528.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.gtxinc.com
GTXI Address
GTXI
175 Toyota Plaza
7th Floor
Memphis, TN 38103
United States
Phone: 901-523-9700
Fax: 901-844-8075
GTXI Latest News
Interactive Technical Analysis Chart GTx, Inc. ( GTXI NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on GTx, Inc.
GTXI Business Profile
GTx, Inc. is a biopharmaceutical company. The Company is developing selective androgen receptor modulators (SARMs) , a drugs with the potential to prevents and treat muscle wasting in patients with cancer and other musculoskeletal wasting or muscle loss conditions, including chronic sarcopenia (age related muscle loss). The Company is conducting the POWER 1 and POWER 2 (Prevention and treatment Of muscles Wasting in patients with cancER) pivotal Phase III clinical trials evaluating enobosarm for the prevention and treatment of muscle wasting in patients with advanced non-small cell lung cancer. In October 2012, it sold rights and related assets in the metastatic breast cancer product, Fareston, to ProStrakan Group plc.